Jane L Yen-Revollo1, J Todd Auman, Howard L McLeod. 1. UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, Campus Box 7360, 3203 Kerr Hall, Chapel Hill, NC 27599-7360, USA.
Abstract
INTRODUCTION: Polymorphic alleles in the human genome have been identified as affecting numerous drug responses. Currently, genotyping of all patients before starting a drug regimen is impractical. Since many polymorphisms occur at varying rates in different racial groups, we investigated whether a patient's race could predict presence of drug-relevant genetic variants well enough to be used as a substitute for individual genotyping. METHODS: We performed hierarchical clustering and principal components analysis on tagSNPs from three pathways (irinotecan, 5-fluorouracil and insulin) across 270 individuals from four racial groups available from the International HapMap Project. RESULTS: For the drug pathways, irinotecan and 5-fluorouracil, individuals from each race were widely dispersed, although several subclusters consisted entirely of individuals from a single racial group. Principal components analysis confirmed race was not a major contributor to the SNP data variance. Interestingly, individuals tended to cluster more by race across the endogenous insulin signaling pathway SNPs. CONCLUSIONS: Most genetic variation was determined by individual variation, not racial grouping, indicating race is not adequate as a surrogate to individualized therapy.
INTRODUCTION: Polymorphic alleles in the human genome have been identified as affecting numerous drug responses. Currently, genotyping of all patients before starting a drug regimen is impractical. Since many polymorphisms occur at varying rates in different racial groups, we investigated whether a patient's race could predict presence of drug-relevant genetic variants well enough to be used as a substitute for individual genotyping. METHODS: We performed hierarchical clustering and principal components analysis on tagSNPs from three pathways (irinotecan, 5-fluorouracil and insulin) across 270 individuals from four racial groups available from the International HapMap Project. RESULTS: For the drug pathways, irinotecan and 5-fluorouracil, individuals from each race were widely dispersed, although several subclusters consisted entirely of individuals from a single racial group. Principal components analysis confirmed race was not a major contributor to the SNP data variance. Interestingly, individuals tended to cluster more by race across the endogenous insulin signaling pathway SNPs. CONCLUSIONS: Most genetic variation was determined by individual variation, not racial grouping, indicating race is not adequate as a surrogate to individualized therapy.
Authors: M S Cepeda; J T Farrar; J H Roa; R Boston; Q C Meng; F Ruiz; D B Carr; B L Strom Journal: Clin Pharmacol Ther Date: 2001-10 Impact factor: 6.875
Authors: M J Millward; M J Boyer; M Lehnert; S Clarke; D Rischin; B-C Goh; J Wong; E McNeil; J F Bishop Journal: Ann Oncol Date: 2003-03 Impact factor: 32.976
Authors: K Shirao; P M Hoff; A Ohtsu; P J Loehrer; I Hyodo; S Wadler; R G Wadleigh; P J O'Dwyer; K Muro; Y Yamada; N Boku; F Nagashima; J L Abbruzzese Journal: J Clin Oncol Date: 2004-07-26 Impact factor: 44.544
Authors: Rachel Huddart; Alison E Fohner; Michelle Whirl-Carrillo; Genevieve L Wojcik; Christopher R Gignoux; Alice B Popejoy; Carlos D Bustamante; Russ B Altman; Teri E Klein Journal: Clin Pharmacol Ther Date: 2019-01-21 Impact factor: 6.875